Parametrica Management Ltd acquired a new position in Teleflex Incorporated (NYSE:TFX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,626 shares of the medical technology company’s stock, valued at approximately $338,000.
Other large investors also recently modified their holdings of the company. Pennsylvania Trust Co raised its stake in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock worth $419,000 after buying an additional 15 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in shares of Teleflex by 3.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,175 shares of the medical technology company’s stock worth $213,000 after buying an additional 35 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Teleflex by 0.6% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,553 shares of the medical technology company’s stock worth $1,270,000 after buying an additional 37 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Teleflex by 0.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,560 shares of the medical technology company’s stock worth $1,271,000 after buying an additional 38 shares during the last quarter. Finally, Creative Planning raised its stake in shares of Teleflex by 3.7% in the first quarter. Creative Planning now owns 2,259 shares of the medical technology company’s stock worth $438,000 after buying an additional 81 shares during the last quarter. Institutional investors and hedge funds own 93.02% of the company’s stock.
Teleflex Incorporated (TFX) traded down 0.45% on Tuesday, reaching $213.64. 110,941 shares of the company were exchanged. Teleflex Incorporated has a 12-month low of $136.53 and a 12-month high of $216.37. The stock has a market capitalization of $9.61 billion, a P/E ratio of 44.34 and a beta of 1.05. The company’s 50-day moving average price is $207.61 and its 200-day moving average price is $195.00.
Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.13. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The firm had revenue of $528.60 million for the quarter, compared to the consensus estimate of $518.98 million. During the same quarter in the prior year, the company posted $1.89 earnings per share. The business’s revenue was up 11.6% on a year-over-year basis. Equities research analysts anticipate that Teleflex Incorporated will post $8.25 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $1.36 annualized dividend and a yield of 0.63%. Teleflex’s payout ratio is 26.00%.
A number of equities research analysts recently commented on the stock. BidaskClub lowered shares of Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, May 20th. Leerink Swann raised their price objective on shares of Teleflex from $215.00 to $220.00 and gave the stock a “market perform” rating in a report on Friday, June 9th. Needham & Company LLC restated a “buy” rating and set a $224.00 price objective on shares of Teleflex in a report on Friday, May 5th. Finally, Jefferies Group LLC restated a “buy” rating and set a $230.00 price objective on shares of Teleflex in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Teleflex presently has a consensus rating of “Buy” and a consensus target price of $221.17.
In other news, Director Stuart A. Randle sold 2,500 shares of the stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $205.67, for a total value of $514,175.00. Following the completion of the sale, the director now owns 7,532 shares in the company, valued at $1,549,106.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $199.93, for a total transaction of $39,986.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at approximately $1,615,434.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,300 shares of company stock worth $1,643,975. Corporate insiders own 2.39% of the company’s stock.
About Teleflex
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
